Skip to main content
SpringerLink
Log in

Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Objectives

To study the frequency of insulin resistance (IR) in endometrial cancer patients, its relation to the clinical course of the disease and DNA damage, and to evaluate possible approaches to the pharmacological correction of IR in the patients studied.

Methods

The signs of insulin resistance syndrome and its association with the clinical and pathological features of the disease and DNA damage in somatic cells (micronucleus frequency in peripheral blood lymphocytes) and endometrial normal and tumor tissue (alkaline unwinding) were determined in 99 endometrial cancer patients.

Results

The frequency of insulin resistance syndrome counted on the basis of fasting plasma glucose and insulin concentrations according to Duncan et al. is equal to 0.35 (95% CI 0.24–0.46), or 35%, in endometrial cancer patients who do not have a history of diabetes mellitus. Patients with well- or moderately differentiated endometrial adenocarcinomas (mostly type I) had statistically significantly higher basal and stimulated plasma insulin and C-peptide concentrations than patients with poorly differentiated endometrial adenocarcinomas or rarely encountered tumors of the endometrium (primarily type II). Interestingly, the level of fasting insulinemia positively correlates with disease stage and with local and regional tumor dissemination only in the group of patients with well- or moderately differentiated endometrial adenocarcinomas. On the other hand, hyperinsulinemia and other hormonal-metabolic disturbances typical of insulin resistance syndrome do not increase the probability of DNA damage of somatic cells (according to the data of micronucleus test). In addition, no association between hormonal-metabolic disturbances and the degree of DNA unwinding in tumor and visually unchanged endometrium was found.

Conclusion

Thus, insulin resistance/hyperinsulinemia is associated with a more aggressive course of the disease in certain groups of the patients but—in contrast to excessive estrogenic stimulation—does not result in increased genotoxic damage in tumor and normal tissues. The data obtained once more confirm the need for treatment and prevention measures aimed at correcting hormonal-metabolic disturbances in endometrial cancer patients and groups at risk of this disease. Such an approach might include use of antidiabetic biguanides, thiazolidinediones (glitazones), and statins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anderson B, Connor JP, Andrews JI, Davis CS, Buller RE, Sorosky JI, Benda JA (1996) Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol 174:1171–1178

    CAS  PubMed  Google Scholar 

  • Berstein LM (2000) Hormonal carcinogenesis. Nauka, St. Peterburg, pp 199

  • Berstein LM, Evtushenko TP, Tsyrlina EV, Bobrov JF, Ostroumova MN, Kovalenko IG, Semiglazov VF, Simonov NN, Dilman VM (1992) Comparative study of 5- and 10-year results of metabolic rehabilitation in oncological patients. In: Hanson KP, Dilman VM (eds) Neuroendocrine system, metabolism, immunity and cancer; clinical aspects. Medicine, St.Petersburg, pp 102–112

  • Berstein LM, Gamajunova VB, Tchernobrovkina AE, Kvatchevskaya JO, Kovalenko IG, Tsyrlina EV, Chepik OF, Maximov S, Ourmantcheeva A (1999) Tissue estrogen content and signs of insulin resistance in endometrial cancer: connection with DNA unwinding in the endometrium and clinico-morphological features of the disease. Eur J Gynecol Oncol 20[Suppl]:51–52

  • Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafian LA, Thijssen JHH (2003) Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 129:245–249

    CAS  PubMed  Google Scholar 

  • Birnboim HC, Jevcak JJ (1981) Fluorimetric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res 42:1889–1892

    Google Scholar 

  • Bokhman JV (1983) Two pathogenetical types of endometrial carcinoma. Gynecol Oncol 15:10–17

    Article  CAS  PubMed  Google Scholar 

  • Bokhman JV (1989) Manual on oncogynecology. Medicine, Leningrad, pp 463

  • Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health 12:749–756

    Google Scholar 

  • Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D (2000) Estrogens as endogenous genotoxic agents—DNA adducts and mutations. J Natl Cancer Inst Monog 27:75–94

    CAS  Google Scholar 

  • Costello MF, Eden JA (2003) Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for PCOD. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79:1–13

    Article  PubMed  Google Scholar 

  • Dilman VM (1987) Four models of medicine. Medicine, Leningrad, pp 287

  • Dilman VM (1994) Development, ageing and disease. A new rationale for an intervention strategy. Harwood Acad, Chur, Switzerland, pp 387

  • Dilman VM, Berstein LM, Ostroumova MN, Fedorov SN, Poroshina TE, Tsyrlina EV, Buslaeva VP, Semiglazov VF, Bobrov JF, Seleznev IK, Vasilieva IA, Kondratiev VB, Nikiforov JF (1982) Metabolic immunodepression and metabolic immunotherapy. An attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 39:13–19

    CAS  PubMed  Google Scholar 

  • Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh P (1995) A simple measure of insulin resistance. Lancet 346:521–522

    Article  PubMed  Google Scholar 

  • Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W (2000) Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7:227–242

    CAS  PubMed  Google Scholar 

  • Facchini FS, Hua N, Abbasi F, Reaven GM (2001) Insulin resistance as a predictor of age-related diseases. J Clin Endocr Metab 86:3574–3578

    Article  CAS  PubMed  Google Scholar 

  • Fenech M, Morley AA (1986) Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo aging and low dose radiation. Mutat Res 161:193–198

    Article  CAS  PubMed  Google Scholar 

  • Gamajunova VB, Bobrov JF, Tsyrlina EV, Evtushenko TP, Berstein LM (1997) Comparative study of blood insulin levels in breast and endometrial cancer. Neoplasma 44:123–126

    PubMed  Google Scholar 

  • Ganina KP, Fedorenko ZP, Kolesnik IF, Glushchenko NN (1999) Corpus uteri cancer morbidity, cytogenetics and a genetic-mathematical analysis of the proband’s pedigrees. Tsitol Genet 33:3–9

    CAS  Google Scholar 

  • Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51

    Article  CAS  PubMed  Google Scholar 

  • Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L (2002) Detection of insulin resistance by simple quantitative insulin sensitivity check indexes QUICKI and HOMA for epidemiological assessment and prevention. J Clin Endocr Metab 87:144–147

    Article  CAS  PubMed  Google Scholar 

  • Jakobisiak M, Golab J (2003) Potential antitumor effects of statins. Int J Oncol 23:1055–1069

    CAS  PubMed  Google Scholar 

  • Kolubaeva SN, Prokopchuk BI, Raketskaya VV, Myasnikova LV, Komar VE (1989) Comparative study of micronucleus assay and chromosomal aberrations in PHA-stimulated human lymphocytes. Radiobiology 30:124–126

    Google Scholar 

  • Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG (2002) Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Brit J Cancer 87:726–728

    Article  CAS  PubMed  Google Scholar 

  • Liehr JG (1997) Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 6:3–10

    CAS  PubMed  Google Scholar 

  • Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108:262–268

    Article  CAS  PubMed  Google Scholar 

  • Nagamani M, Hannigan EV, Tung D, Stuart CA (1988) Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocr Metab 67:144–148

    CAS  PubMed  Google Scholar 

  • Nestler JE (1993) Sex-hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocr Metab 76:273–274

    Article  CAS  PubMed  Google Scholar 

  • Randolph JF, Kipersztok S, Ayers JWT, Ansbacker R, Peegal H, Menon KMJ (1987) The effect of insulin on aromatase activity in isolated human endometrial glands and stroma. Am J Obstetr Gynecol 157:1534–1539

    CAS  Google Scholar 

  • Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1495–1607

    Google Scholar 

  • Rutanen EM, Nyman T, Lehtovirta P, Ammala M, Pekonen F (1994) Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer 59:307–312

    CAS  PubMed  Google Scholar 

  • Schneider M, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263–1270

    Google Scholar 

  • Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295–308

    Article  CAS  PubMed  Google Scholar 

  • Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA (1997) Insulin and endomelrial cancer. Am J Epidemiol 146:476–482

    CAS  PubMed  Google Scholar 

  • Tsujie M, Nakamori S, Okami J, Hayashi N, Monden M (2003) Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res 289:143–151

    Article  CAS  PubMed  Google Scholar 

  • Vishnevsky AS, Bobrov JF, Tsyrlina EV, Dilman VM (1993) Hyperinsulinemia as a factor modifying sensitivity of endometrial carcinoma to hormonal influences. Eur J Gynecol Oncol 14:127–130

    CAS  Google Scholar 

  • Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R (2003) Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer 89:1697–1704

    Article  CAS  PubMed  Google Scholar 

  • Wojda A, Witt M (2003) Manifestations of ageing at the cytogenetic level. J Appl Genet 44:383–399

    PubMed  Google Scholar 

Download references

Acknowledgements

This study was partly supported by grants from INTAS (01–434) and RFBR (03–04–49282)

Author information

Authors and Affiliations

  1. Lab. Oncoendocrinology, N.N. Petrov Research Institute of Oncology, Pesochny-2, 197758, St. Petersburg, Russia

    L. M. Berstein, T. E. Poroshina, I. G. Kovalenko, E. V. Tsyrlina & T. S. Zimarina

  2. Medical Academy of Postgraduate Study, St. Petersburg, Russia

    J. O. Kvatchevskaya & A. F. Ourmantcheeva

  3. Gynecological Dept, Russian Center of Roentgenology and Radiology, Moscow, Russia

    L. Ashrafian

  4. ASL Endocrinology, University Medical Center, Utrecht, The Netherlands

    J. H. H. Thijssen

Authors
  1. L. M. Berstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. O. Kvatchevskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. E. Poroshina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. G. Kovalenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. V. Tsyrlina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. S. Zimarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. F. Ourmantcheeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Ashrafian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. H. H. Thijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. M. Berstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berstein, L.M., Kvatchevskaya, J.O., Poroshina, T.E. et al. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol 130, 687–693 (2004). https://doi.org/10.1007/s00432-004-0587-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-004-0587-2

Keywords

Search

Navigation